Prof. Jihui Hao 郝继辉
Chief Physician, Professor
Department of Pancreatic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of pancreatic tumors, including complex procedures such as pancreaticoduodenectomy with portal vein resection and reconstruction, extended lymph node dissection, and function-preserving pancreatectomy.
Dr. Hao is Vice President of Tianjin Medical University Cancer Institute & Hospital and Director of the Pancreatic Tumor Department. Dr. Hao earned a medical degree in 1995 and a PhD in Oncology in 2002 from Tianjin Medical University, followed by postdoctoral work at the University of London (2002–2004). Research focuses on pancreatic cancer metastasis, immune regulation, and personalized therapy.
Professional roles
- Standing Committee Member, Pancreatic Disease Group, China Anti-Cancer Association
- Standing Committee Member, Pancreatic Tumor Professional Committee, China Anti-Cancer Association
- Executive Editorial Board Member, Chinese Journal of Clinical Oncology
- Member, American Cancer Research Foundation
Name order: in Chinese the family name comes first (Hao Jihui). Papers usually list the name as Jihui Hao or Hao J.
Selected publications
178 papers on PubMed matched by name and affiliation; 78 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Transl Med, 2026 (senior author): Albumin-bound paclitaxel-induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer. PubMed 43013678
- Signal Transduct Target Ther, 2026 (senior author): Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial. PubMed 42971953
- Cancer Biol Med, 2026 (senior author): An integrated CT/MRI diagnostic system for pancreatic cystic lesions that supports pathological classification and risk stratification. PubMed 42972650
- Cell, 2026 (senior author): STING reprogramming by estrogen promotes neutrophil extracellular trap formation and sex-biased resistance to ADC therapy. PubMed 42838045
- Gut, 2026 (senior author): Short-term risk prediction model for pancreatic cancer in type 2 diabetes: development and validation across two independent Chinese cohorts. PubMed 42838738
- J Med Chem, 2026 (senior author): TGF-β-Targeting Platinum(IV) Prodrugs Remodel Tumor Microenvironment of Pancreatic Cancer via Antifibrotic and Immunomodulatory Effects. PubMed 42916697
- Gut, 2026 (senior author): Trogocytosis-orchestrated CLDN18.2-"dressed" CD8(+) T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade. PubMed 41667243
- Cancer Discov, 2026 (senior author): Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. PubMed 41891402
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion